Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma

Latha Shivakumar, James Olen Armitage

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35%-60%. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximab-containing treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53%) and 137 had received CHOP (47%). One hundred ninety-three patients (66%) were found to express high levels of Bcl-2 protein in > 50% of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56% vs. 42%; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58% vs. 52%; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy.

Original languageEnglish (US)
Pages (from-to)455-457
Number of pages3
JournalClinical Lymphoma and Myeloma
Volume6
Issue number6
DOIs
StatePublished - May 2006

Fingerprint

bcl-2 Genes
Lymphoma, Large B-Cell, Diffuse
Gene Expression
Drug Therapy
Survival Rate
Vincristine
Prednisone
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Lymphoma
Therapeutics

Keywords

  • CHOP
  • Nuclear factor-κB
  • Rituximab
  • Survival
  • Translocations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma. / Shivakumar, Latha; Armitage, James Olen.

In: Clinical Lymphoma and Myeloma, Vol. 6, No. 6, 05.2006, p. 455-457.

Research output: Contribution to journalReview article

@article{9b701613a1d045d1b08c1e71b0316e1b,
title = "Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35{\%}-60{\%}. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximab-containing treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53{\%}) and 137 had received CHOP (47{\%}). One hundred ninety-three patients (66{\%}) were found to express high levels of Bcl-2 protein in > 50{\%} of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56{\%} vs. 42{\%}; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58{\%} vs. 52{\%}; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy.",
keywords = "CHOP, Nuclear factor-κB, Rituximab, Survival, Translocations",
author = "Latha Shivakumar and Armitage, {James Olen}",
year = "2006",
month = "5",
doi = "10.3816/CLM.2006.n.025",
language = "English (US)",
volume = "6",
pages = "455--457",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",

}

TY - JOUR

T1 - Bcl-2 gene expression as a predictor of outcome in diffuse large B-cell lymphoma

AU - Shivakumar, Latha

AU - Armitage, James Olen

PY - 2006/5

Y1 - 2006/5

N2 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35%-60%. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximab-containing treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53%) and 137 had received CHOP (47%). One hundred ninety-three patients (66%) were found to express high levels of Bcl-2 protein in > 50% of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56% vs. 42%; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58% vs. 52%; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy.

AB - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with a 5-year survival rate of 35%-60%. Various clinical factors included in the International Prognostic Index have failed to identify the patients with DLBCL who will not benefit from the standard R-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone plus rituximab) treatment regimen. Bcl-2 has been implicated in conferring resistance to chemotherapy in non-Hodgkin's lymphoma and is therefore a candidate prognostic marker in DLBCL. To identify the correlation between Bcl-2 expression and response to rituximab-containing treatment regimens, histologic materials were analyzed from 292 elderly patients with confirmed DLBCL. Of these, 155 patients had received R-CHOP (53%) and 137 had received CHOP (47%). One hundred ninety-three patients (66%) were found to express high levels of Bcl-2 protein in > 50% of the tumor cells. Of the 193 Bcl-2-positive patients, the patients who received R-CHOP had a better 5-year overall rate than patients treated with CHOP (56% vs. 42%; P = 0.01), whereas in the patients with Bcl-2-negative disease, there was no statistically significant difference in the 5-year overall survival rates between the R-CHOP and CHOP regimens (58% vs. 52%; P = 0.6). Therefore, the addition of rituximab to the standard chemotherapy regimen seems to have overcome the Bcl-2-associated resistance to chemotherapy.

KW - CHOP

KW - Nuclear factor-κB

KW - Rituximab

KW - Survival

KW - Translocations

UR - http://www.scopus.com/inward/record.url?scp=33745890271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745890271&partnerID=8YFLogxK

U2 - 10.3816/CLM.2006.n.025

DO - 10.3816/CLM.2006.n.025

M3 - Review article

C2 - 16796775

AN - SCOPUS:33745890271

VL - 6

SP - 455

EP - 457

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 6

ER -